Advertisement

Topics

PubMed Journals Articles About "Takeda TiGenix Announce Publication Lancet Week Results Phase" RSS

04:04 EDT 18th June 2018 | BioPortfolio

Takeda TiGenix Announce Publication Lancet Week Results Phase PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Takeda TiGenix Announce Publication Lancet Week Results Phase articles that have been published worldwide.

More Information about "Takeda TiGenix Announce Publication Lancet Week Results Phase" on BioPortfolio

We have published hundreds of Takeda TiGenix Announce Publication Lancet Week Results Phase news stories on BioPortfolio along with dozens of Takeda TiGenix Announce Publication Lancet Week Results Phase Clinical Trials and PubMed Articles about Takeda TiGenix Announce Publication Lancet Week Results Phase for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Takeda TiGenix Announce Publication Lancet Week Results Phase Companies in our database. You can also find out about relevant Takeda TiGenix Announce Publication Lancet Week Results Phase Drugs and Medications on this site too.

Showing "Takeda TiGenix Announce Publication Lancet Week Results Phase" PubMed Articles 1–25 of 48,000+

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results.

The 24-week equivalent efficacy and comparable safety results of SB5 and reference adalimumab (ADA) from the phase 3 randomized study in patients with moderate to severe rheumatoid arthritis (RA) have been reported previously. This transition study evaluated patients who switched from ADA to SB5 or continued on SB5 or ADA up to 52 weeks.


Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial.

Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.

This phase III clinical trial compared the immunogenicity and safety of a purified chick-embryo cell rabies vaccine (PCECV) administered according to a shortened post-exposure prophylaxis (PEP) 4-site/1-week intradermal regimen, compared with the currently recommended 2-site/Thai Red Cross (TRC).


25th UEG Week.

Measurement of three-dimensional wavefronts using the Ichikawa-Lohmann-Takeda solution to the irradiance transport equation.

In this paper, we use the irradiance transport equation and the Fourier transform-based experimental solution given by Ichikawa-Lohmann-Takeda. We analyze experimental factors such as the digital filter, the introduced error for the rotation and period of the Ronchi ruling, and a new method is demonstrated for the measurement of 3D wavefront information.

Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated efficacy and safety in systemic-naive patients with chronic moderate plaque psoriasis with lower psoriasis-involved body surface area (BSA; 5%-10%) during the 16-week, double-blind, placebo-controlled phase. We describe efficacy and safety of apremilast in this population through week 52 in UNVEIL. METHODS: Patients with moderate plaque ps...

Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: Week 96 results from ONCEMRK, a randomized, double-blind, non-inferiority trial.

Raltegravir 1200mg (2x600mg tablets) once daily (QD) demonstrated non-inferior efficacy and similar safety to raltegravir 400mg BID at Week 48 of the ONCEMRK trial. Here we report the Week 96 results from this study.

Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.

Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC). Increasingly, low-dose once-a-week cisplatin is substituted because of perceived lower toxicity and convenience. However, there is no level 1 evidence of comparable efficacy to cisplatin once every 3 weeks. Patients and Methods In this phase III randomized trial, we assessed the noninferiority of cisplatin 30 mg/m2 given once a week compared with ...

Initiation and publication time-lags of treatment trials for Ebola virus disease.

Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial.

Neutralizing interleukin (IL)-17F in addition to IL-17A may provide a more complete and specific approach to inhibiting inflammation.

Effects of Single Set Resistance Training With Different Frequencies on a Cellular Health Indicator in Older Women.

The main purpose of this study was compare the effects of resistance training (RT) performed two versus three times per week on phase angle (a cellular health indicator) in older women. Thirty-nine women (69.1±5.5 years) were randomly assigned to perform a RT program two (G2X) or three (G3X) days per week for 12 weeks. The RT was a whole-body program (8 exercises, 1 set, 10-15 repetitions). Phase angle, resistance, reactance, and total body water were assessed by bioimpedance spectroscopy. Intracellular wa...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Millennium Pharmaceuticals, and Onyx Pharmaceuticals; and is a member of advisory boards for Amgen, Bristol-Myers Squibb, Celgene Corporation, Incyte, Kite, Legend Biotech, Sanofi-Aventis, and Takeda Pharmaceuticals.

An Investigation Into the Effects of Excluding the Catch Phase of the Power Clean on Force-Time Characteristics During Isometric and Dynamic Tasks: An Intervention Study.

Comfort, P, Dos'Santos, T, Thomas, C, McMahon, JJ, and Suchomel, TJ. An investigation into the effects of excluding the catch phase of the power clean on force-time characteristics during isometric and dynamic tasks: an intervention study. J Strength Cond Res XX(X): 000-000, 2018-The aims of this study were to compare the effects of the exclusion or inclusion of the catch phase during power clean (PC) derivatives on force-time characteristics during isometric and dynamic tasks, after two 4-week mesocycles o...

Correction to Lancet Oncol 2017; 18: 1565-66.

Correction to Lancet Oncol 2017; 18: 1493-501.

Correction to Lancet Respir Med 2018; 6: e2.

Germany's delayed coal phase-out and respiratory health.

A randomized, multicentre phase III study of three different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.

Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) show varying degrees of response to intravenous immunoglobulin (IVIg) therapy. This randomised phase III study in patients with CIDP (ProCID trial) will compare the efficacy and safety of three different doses (0.5, 1.0 and 2.0 g/kg) of IVIg 10% (panzyga®) administered every 3 weeks for 24 weeks. The primary efficacy endpoint is the rate of treatment response, defined as a decrease in adjusted Inflammatory Neuropathy Cause and T...

Accelerate progress-sexual and reproductive health and rights for all: report of the Guttmacher-Lancet Commission.

Twelve-week Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.

The need for all-oral HCV treatments with higher response rates, improved tolerability and lower pill burden compared to interferon-inclusive regimen has led to the development of new direct-acting antiviral agents (DAAs). Ravidasvir (RDV) is a second-generation, pan-genotypic NS5A inhibitor with high barrier to resistance. The aim of this phase 2 study (EVERST study) was to assess the efficacy and safety of interferon-free, 12-week RDV plus ritonavir-boosted danoprevir (DNVr) and ribavirin (RBV) regimen fo...

Absolute sensitivity of phase measurement in an SU(1,1) type interferometer.

Absolute sensitivity is measured for the phase measurement in an SU(1,1) type interferometer, and the results are compared to that of a Mach-Zehnder interferometer operated under the condition of the same intra-interferometer intensity. The interferometer is phase locked to a point with the largest quantum noise cancellation, and a simulated phase modulation is added in one arm of the SU(1,1) interferometer. Both the signal and noise level are estimated at the same frequency range, and we obtained 3 dB imp...

Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.

Tofacitinib is an oral Janus kinase inhibitor. This post-hoc analysis aimed to investigate the psychometric properties of the Itch Severity Item (ISI), a numeric rating scale from 0 (no itching) to 10 (worst possible itching) for pruritus in psoriasis, and review the effect of tofacitinib on pruritus in patients with psoriasis participating in Phase 3 studies (n = 3,641). The ISI showed high test-retest reliability (intra-class correlation coefficient: 0.84). The clinically important difference was defi...

Preparation and biocompatibility evaluation of polypropylene mesh coated with electrospinning membrane for pelvic defects repair.

Composite mesh with different materials composition could compensate for the drawbacks brought by single component mesh. Coating a membrane layer on the surface of macroporous mesh is a common method for preparing composite medical mesh. Electrospinning and dipping methods were introduced to form the two kinds of membrane-coated PP meshes (electro-mesh and dip-mesh); several properties were measured based on subcutaneous implantation model in rat. The results revealed that continuous tissue ingrowth could b...

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

Objectives Ontuxizumab (MORAB-004) is a first-in-class monoclonal antibody that interferes with endosialin function, which is important in tumor stromal cell function, angiogenesis, and tumor growth. This Phase 2 study evaluated the 24-week progression-free survival (PFS) value, pharmacokinetics, and tolerability of 2 doses of ontuxizumab in patients with metastatic melanoma. Patients and methods Patients with metastatic melanoma and disease progression after receiving at least 1 prior systemic treatment we...

Physical significance of backscattering phase measurements.

Quantitative phase imaging of transparent objects in transmission allows for a direct interpretation of the results: the phase shift measured is linear in the refractive index contrast and object thickness. However, the same measurement in a backscattering geometry yields fundamentally different results, because the incident field component is absent from the detected field. As a result, the relationship between the measured phase and object properties is obscure. We derived analytical expressions for the p...


Advertisement
Quick Search
Advertisement
Advertisement